Navigation Links
Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
Date:4/29/2008

PRINCETON, N.J., April 29 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that the following clinical and preclinical abstracts for ipilimumab in melanoma, prostate cancer and other cancers, as well as for anti-PD-1 and anti-CD70 antibody candidates for cancer treatment, are expected to be the subject of presentations at the Annual Meeting of the American Society of Clinical Oncology, being held May 30-June 3, 2008 in Chicago:

Survival, Response, Safety and Biomarker Data of Ipilimumab in Melanoma

-- "Antitumor response and new lesions in advanced melanoma patients on

ipilimumab treatment" (Abstract #3020, Developmental Therapeutics:

Immunotherapy Session) -- Poster presentation and discussion from 2:00

p.m. to 6:00 p.m. local time on Friday, May 30, 2008.

-- "Long-term survival of patients with advanced melanoma who received

ipilimumab administered at 10mg/kg every 3 weeks for 4 doses (induction

dosing)" (Abstract #3018, Developmental Therapeutics: Immunotherapy

Session) - Poster presentation and discussion from 2:00 p.m. to 6:00

p.m. local time on Friday, May 30, 2008.

-- "Potential immune biomarkers of gastrointestinal toxicities and

efficacy in patients with advanced melanoma treated with ipilimumab

with or without prophylactic budesonide" (Abstract #3022, Developmental

Therapeutics: Immunotherapy Session) -- Poster presentation and

discussion from 2:00 p.m. to 6:00 p.m. local time on Friday, May 30,

2008.

-- "Novel efficacy criteria for antitumor activity to immunotherapy using

the example of ipilimumab, an anti-CTLA-4 monoclonal antibody"

(Abstract #3008, Developmental Therapeutics: Immunotherapy

Session) -- Oral presentation beginning at 4:30 p.m. local time one

Saturday, May 31, 2008.

-- "Effect of prior treatment status on the efficacy and safety of

ipilimumab monotherapy in treatment-naive and previously treated

patients with advanced melanoma" (Abstract #9055, Melanoma

Session) -- Poster presentation from 2:00 p.m. to 6:00 p.m. local time

on Saturday, May 31, 2008.

-- "An analysis of the effectiveness of specific guidelines for the

management of ipilimumab-mediated diarrhea/colitis: prevention of

gastrointestinal perforation and/or colectomy" (Abstract #9063,

Melanoma Session) - Poster presentation from 2:00 p.m. to 6:00 p.m.

local time on Saturday, May 31, 2008.

-- "Model-based evaluation of ipilimumab dosage regimen in patients with

advanced melanoma" (Abstract #9073, Melanoma Session) -- Poster

presentation from 2:00 p.m. to 6:00 p.m. local time on Saturday, May

31, 2008.

-- "Safety and efficacy of ipilimumab with or without prophylactic

budesonide in treatment-naive and previously treated patients with

advanced melanoma" (Abstract #9010, Melanoma Session) -- Oral

presentation beginning at 10:15 a.m. local time on Sunday, June 1,

2008.

-- "Efficacy and safety of ipilimumab induction and maintenance dosing in

patients with advanced melanoma who progressed on one or more prior

therapies" (Abstract #9021, Melanoma Session) -- Poster presentation

and discussion from 2:00 p.m. to 6:00 p.m. local time on Sunday, June

1, 2008.

-- "Disease control and long-term survival in chemotherapy-naive patients

with advanced melanoma treated with ipilimumab (MDX-010) with or

without dacarbazine" (Abstract #9022, Melanoma Session) -- Poster

presentation and discussion from 2:00 p.m. to 6:00 p.m. local time on

Sunday, June 1, 2008.

-- "Dose effect of ipilimumab in patients with advanced melanoma: results

from a phase 2, randomized, dose-ranging study" (Abstract #9025,

Melanoma Session) -- Poster presentation and discussion from 2:00 p.m.

to 6:00 p.m. local time on Sunday, June 1, 2008.

-- "Prolonged survival in objective responders to ipilimumab therapy"

(Abstract #20004) -- Publication only.

Response and Safety Data of Ipilimumab in Prostate

-- "Phase 1 trial of ipilimumab (IPI) alone and in combination with

radiotherapy (XRT) in patients with metastatic castration resistant

prostate cancer (mCRPC)" (Abstract #5004, New Targeted Strategies for

Patients with Prostate Cancer Session) -- Oral presentation beginning

at 11:30 a.m. local time on Monday, June 2, 2008.

-- "Expanded phase 1 combination trial of GVAX immunotherapy for prostate

cancer and ipilimumab in patients with metastatic hormone-refractory

prostate cancer (mHRPC)" (Abstract #5146, Genitourinary Cancer Session)

-- Poster presentation from 8:00 a.m. to 12:00 p.m. local time on

Saturday, May 31, 2008.

Clinical and Preclinical Data of Additional Immunotherapy and Antibody-Drug Conjugate Programs

-- "Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal

antibody, in patients with selected refractory or relapse malignancies"

(Abstract #3006, Developmental Therapeutics: Immunotherapy

Session) -- Oral presentation beginning at 4:00 p.m. local time on

Saturday, May 31, 2008.

-- "Antitumor activity of anti-CTLA-4 monoclonal antibody (mAb) in

combination with ixabepilone in preclinical tumor models" (Abstract

#3048, Developmental Therapeutics: Immunotherapy Session) -- Poster

presentation from 2:00 p.m. to 6:00 p.m. local time on Sunday, June 1,

2008.

-- "Effect of a fully human anti-CD70 antibody on apoptosis and

dephosphorylation of MAPK proteins in chronic lymphocytic leukemia"

(Abstract #3073, Developmental Therapeutics: Immunotherapy

Session) -- Poster presentation from 2:00 p.m. to 6:00 p.m. local time

on Sunday, June 1, 2008.

More information about the ASCO Annual Meeting may be found at http://www.asco.org.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
2. Medarex Announces Ipilimumab Program Continues to Move Forward
3. Medarex to Receive Milestone Payment from Amgen
4. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
7. XTENT Announces First Quarter 2008 Financial Results
8. Neuralstem Announces Issuance of Core Technology Patent in Europe
9. ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment
10. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
11. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... and PITTSBURGH, Feb. 10, 2016 Mylan N.V. (NASDAQ, ... quarter and year ended December 31, 2015. ... Full year adjusted total revenues of $9.45 billion, up ... year; GAAP total revenues of $9.43 billion. Excluding the ... markets specialty and branded generics business (the "EPD Business"), ...
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
(Date:2/10/2016)... , Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC ... a 1-for-100 reverse split of its issued and outstanding ... trading on Thursday, February 11, 2016. The Company,s common ... CUSIP number 76303T308 and temporary ticker symbol "RCHAD". After ... under the ticker symbol (RCHA).  --> ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... LaserShip, a regional parcel carrier that services the ... Eastern Michigan last Friday in order to aid in the Flint water crisis. In ... a facility located in Clio, only 15 miles away from Flint. , “We have ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand ... within Healthcare, recently partnered with Heart City Health Center to improve ... 23 years, Heart City Health Center has provided the Elkhart community with access ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... 10 ... Brand. There were three leading bottled water brand owners that topped the list as ... enhance connectivity and optimize conversion. The premier brand was Tibet 5100, a top notch ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... welcomes S.S. Nesbitt as the latest addition to its growing list of Partner ... locations throughout the Southeast, from Orlando to Huntsville and in between. , Harnessing ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged to ... shows that the Goal Attainment Scale (GAS) captures 20% more change in outcomes ... more about the Goal Attainment Scale, Education Resources Inc. is offering a course ...
Breaking Medicine News(10 mins):